Perseus Proteomics, Inc. (JP:4882) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Perseus Proteomics, Inc. has announced the publication of an abstract for its radiopharmaceutical therapy, PPMX-T002, aimed at treating solid cancers, at the EANM ’24 Annual Congress. PPMX-T002 targets the cadherin 3 protein on various solid tumors and has shown enhanced efficacy in preclinical trials when using Actinium 225 compared to Yttrium 90.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.